Candidate Review and Sample Evaluation Path

Begin with one candidate and one formula type. This is a proposed workflow, not a completed compatibility study or an instruction to ship.

Step 1 Initial fit review

The customer identifies a candidate, a formula format and the colleague who evaluates new ingredients. We share existing non-confidential evidence and the corresponding technical-evaluation TDS. No purchase order or confidential full formula is required for this first exchange.

Step 2 Agree the evaluation gate

Confirm whether a China-based manufacturer and pending INCI naming are acceptable for initial screening, the intended market, required safety/quality documents, sample specification, importer/consignee and a named evaluator. An NDA is used only where confidential information will be exchanged.

Step 3 Review documents before dispatch

QA must approve actual material identity, composition, net fill, reference mapping and the batch-release decision. Reviewed SDS, actual-batch COA, storage/transport and use-by or retest instructions and destination import arrangements must be accepted before any sample leaves the manufacturer. Free samples require the same review; this plan authorizes no shipment.

Define a usable test record

Record	Agree before testing
Material	Candidate, batch, excipients, actual concentration or per-vial particle count
Formula	Format, preparation size, pH, preservative/solvent system and mixing conditions
Control	Appropriately matched base and excipient control, where feasible
Decision	Measurements, acceptance criteria, evaluator and next review date

Sample fees, first-order credits, MOQ, customization, price, lead time and payment terms are quoted for the agreed scope. Freight and import charges are borne by the buyer unless otherwise agreed in writing. No order, exclusivity or paid study is created by this plan.

Naming status

INCI naming applications have been submitted. Results are expected in late November 2026, subject to review; neither the date nor the outcome is guaranteed. Naming does not establish ingredient safety or destination-market authorization.

Provisional laboratory handling

The company-confirmed analytical particle records use 5 mL reconstitution. R&D separately proposes purified water to a final volume of 3 mL for formulation screening; concentration and recovery at 3 mL have not been measured in the supplied records. Do not treat the 5 mL result as a 3 mL measured concentration.

R&D proposes cool-down addition below 40 C with gentle mixing and an initial pH 5-8 screen. Sealed storage at 4 C, use within 2 hours at 4 C after reconstitution, and avoiding strong oxidants, high shear, concentrated electrolytes or repeated freeze-thaw are provisional recommendations, not validated stability or transport limits. Follow the reviewed instructions for the actual sample before testing.

Proposed observations

Stage	Observation and decision
Before dispatch	Confirm documentation, QA release and consignee/import route
Day 0	Record receipt, reconstitution, actual dose, formula addition, temperature, pH and appearance
Day 3	Compare dispersion, precipitation, separation, color and odor against agreed controls
Day 14	Review agreed interim physical measurements and observations
Day 30	Stop, reformulate, extend assessment or define a pilot quotation

These intervals are a planning example, not a stability validation or promised result. Methods, conditions and acceptance criteria are agreed with the evaluator. Any particle-retention or potency assessment requires suitable methods and separately scoped resources. Initial compatibility does not establish safety, shelf life or finished-product efficacy.

Available evidence and its limits

The corresponding v0.2 TDS and historical reference-lot records support technical review. RPS counts detected particles, not proven EV purity or biological activity. BCA reports sample protein, not EV solid mass. Completed candidate-specific application and stability data are not supplied by this plan.

Contact: runji.yang@ecytobiotech.com | https://ecytobiotech.com
Technical basis: three ECY-TDS v0.2 files, 19 October 2026. Non-clinical formulation evaluation only.